Why does resistance to Mobotinib occur? How to respond effectively?

Mobotinib, as a tyrosine kinase inhibitor (TKI) targeted drug, plays an important role in the treatment of non-small cell lung cancer. It slows or stops cancer growth by blocking tyrosine kinases, proteins that cells use to signal each other to promote growth. However, although mobotinib brings therapeutic hope to many patients, some patients will still develop drug resistance over time.

The generation of drug resistance is a complex process and is closely related to the biological characteristics of tumor cells. During treatment, tumor cells may evade the inhibitory effects of mobotinib through genetic mutations, chromosomal abnormalities, or other mechanisms. These mutations may make tumor cells less sensitive to mobotinib, resulting in reduced efficacy of the drug. For example, the T790M mutation in the EGFR gene is a common cause of resistance to mobotinib.

Facing the problem of resistance to mobotinib, patients and doctors need to work closely and adopt active and effective response strategies. On the one hand, patients should pay close attention to changes in their condition and report any possible signs of drug resistance to their doctors in a timely manner. On the other hand, doctors can adjust the treatment plan according to the patient's specific situation, such as switching to other TKI drugs, using other targeted drugs in combination, or using immunotherapy. These strategies aim to inhibit the growth of tumor cells through different mechanisms of action, thereby overcoming the problem of drug resistance.

In addition, researchers are continuously working to explore new treatment strategies to overcome resistance to mobotinib. For example, by developing new targeted drugs to accurately target drug-resistant mutations; or by combining multiple treatments to enhance the therapeutic effect and reduce the occurrence of drug resistance. In short, although the problem of resistance to mobotinib is a challenge, through the joint efforts of patients, doctors and researchers, it is expected to find a more effective response strategy and provide patients with more durable and effective treatment options.

References:

https://www.cancerresearchuk.org/about-cancer/treatment/drugs/mobocertinib

xa0